NCT02556021View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Non Erosive Reflux Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

324

Participants

Timeline

Start Date

September 22, 2015

Primary Completion Date

November 1, 2016

Study Completion Date

November 1, 2016

Conditions
Non-erosive Reflux Disease
Interventions
DRUG

CJ-12420 50mg

CJ-12420 50mg, tablet, once daily, oral administration for up to 4 weeks

DRUG

CJ-12420 100mg

CJ-12420 100mg, tablet, once daily, oral administration for up to 4 weeks

DRUG

Placebo

Placebo, tablet, once daily, oral administration for up to 4 weeks

Trial Locations (1)

Unknown

Yeouido St.Mary's Hospital, Seoul

Sponsors
All Listed Sponsors
lead

HK inno.N Corporation

INDUSTRY